Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000077.xml
Download PDF
Semin Thromb Hemost 2004; 30(5): 569-577
DOI: 10.1055/s-2004-835677
DOI: 10.1055/s-2004-835677
Thrombocytopenia Resulting from Sensitivity to GPIIb-IIIa Inhibitors
Further Information
Publication History
Publication Date:
21 October 2004 (online)
Agents that inhibit the binding of fibrinogen to its platelet receptor (glycoprotein [GP] IIb-IIIa, αIIb/β3 integrin) constitute a promising new group of antithrombotic drugs. Acute thrombocytopenia, often occurring within a few hours of starting treatment, is a recognized side effect of this family of compounds. Although most affected patients recover uneventfully, severe bleeding and fatal outcomes have been described. Both nonimmune and immune mechanisms have been implicated in the pathogenesis of this complication, but accumulating evidence suggests that drug-dependent antibodies are responsible for platelet destruction in many (and perhaps most) affected individuals. These antibodies are unique in that they can be present in persons not previously exposed to a GPIIb-IIIa inhibitor, allowing for the possibility that thrombocytopenia can occur within hours of starting treatment. Additional studies are needed to more fully define the characteristics of these antibodies and to identify risk factors that predispose patients to this complication.
KEYWORDS
GPIIb-IIIa inhibitors - thrombocytopenia - abciximab - tirofiban - eptifibatide
REFERENCES
- 1 Coller B S. Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics. J Clin Invest. 1997; 99 1467-1471
- 2 Verstraete M. Synthetic inhibitors of platelet glycoprotein IIb/IIIa in clinical development. Circulation. 2000; 101 E76-E80
- 3 Bennett J S, Mousa S. Platelet function inhibitors in the year 2000. Thromb Haemost. 2001; 85 395-400
- 4 Topol E J, Byzova T V, Plow E F. Platelet GPIIb-IIIa blockers. Lancet. 1999; 353 227-231
- 5 Kereiakes D J. Oral platelet glycoprotein IIb/IIIa inhibitors. Coron Artery Dis. 1999; 10 581-594
- 6 Tam S H, Sassoli P M, Jordan R E, Nakada M T. Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins. Circulation. 1998; 98 1085-1089
- 7 Nurden P, Poujol C, Durrieu-Jais C et al.. Labeling of the internal pool of GP IIb-IIIa in platelets by c7E3 Fab fragments (abciximab): flow and endocytic mechanisms contribute to the transport. Blood. 1999; 93 1622-1633
- 8 Christopoulos C, Mackie I, Lahiri A, Machin S. Flow cytometric observations on the in vivo use of Fab fragments of a chimeric monoclonal antibody to platelet glycoprotein IIb/IIIa. Blood Coagul Fibrinolysis. 1993; 4 729-737
- 9 Mascelli M A, Lance E T, Damaraju L, Wagner C L, Weisman H F, Jordan R E. Pharmaco-dynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GPIIb/IIIa receptor blockade. Circulation. 1998; 97 1680-1686
- 10 EPILOG Investigators . Platelet glycoprotein IIb/IIIa receptor blockade and low dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997; 336 1689-1696
- 11 CAPTURE investigators . Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study. Lancet. 1997; 349 1429-1435
- 12 Berkowitz S D, Sane D C, Sigmon K N et al.. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. J Am Coll Cardiol. 1998; 32 311-319
- 13 Jubelirer S J, Koenig B A, Bates M C. Acute profound thrombocytopenia following C7E3 Fab (abciximab) therapy: case reports, review of the literature and implications for therapy. Am J Hematol. 1999; 61 205-208
- 14 Tcheng J E, Kereiakes D J, Lincoff A M et al.. Abciximab readministration: results of the ReoPro Readministration Registry. Circulation. 2001; 104 870-875
- 15 Kereiakes D J, Berkowitz S D, Lincoff A M et al.. Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade. Am Heart J. 2000; 140 74-78
- 16 Dillon W C, Eckert G J, Dillon J C, Ritchie M E. Incidence of thrombocytopenia following coronary stent placement using abciximab plus clopidogrel or ticlopidine. Catheter Cardiovasc Interv. 2000; 50 426-430
- 17 Guzzo J A, Nichols T C. Possible anaphylactic reaction to abciximab. Catheter Cardiovasc Interv. 1999; 48 71-73
- 18 Iakovou Y, Manginas A, Melissari E, Cokkinos D V. Acute profound thrombocytopenia associated with anaphylactic reaction after abciximab therapy during percutaneous coronary angioplasty. Cardiology. 2001; 95 215-216
- 19 Curtis B R, Swyers J, Divgi A, McFarland J G, Aster R H. Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets. Blood. 2002; 99 2054-2059
- 20 Vahdat B, Canavy I, Fourcade L et al.. Fatal cerebral hemorrhage and severe thrombocytopenia during abciximab treatment. Catheter Cardiovasc Interv. 2000; 49 177-180
- 21 Moshiri S, Di Mario C, Liistro F, Melissano G, Chiesa R, Colombo A. Severe intracranial hemorrhage after emergency carotid stenting and abciximab administration for postoperative thrombosis. Catheter Cardiovasc Interv. 2001; 53 225-228
- 22 Jenkins L A, Lau S, Crawford M, Keung Y K. Delayed profound thrombocytopenia after c7E3 Fab (abciximab) therapy. Circulation. 1998; 97 1214-1215
- 23 Reddy M S, Carmody T J, Kereiakes D J. Severe delayed thrombocytopenia associated with abciximab (ReoPro) therapy. Catheter Cardiovasc Interv. 2001; 52 486-488
- 24 Kaluski E, Leitman M, Khiger I, Cotter G. Delayed thrombocytopenia following abciximab therapy. J Cardiovasc Interv. 2001; 4 151-155
- 25 Sharma S, Bhambi B, Nyitray W et al.. Delayed profound thrombocytopenia presenting seven days after use of abciximab (ReoPro). J Cardiovasc Pharmacol Ther. 2002; 7 21-24
- 26 Desai M, Lucore C L. Uneventful use of tirofiban as an adjunct to coronary stenting in a patient with a history of abciximab-associated thrombocytopenia 10 months earlier. J Invasive Cardiol. 2000; 12 109-112
- 27 Coto H. Platelet receptor glycoprotein IIb/IIIa inhibition with eptifibatide in a patient with thrombocytopenia after treatment with abciximab. J Invasive Cardiol. 2000; 12 528-531
- 28 Aster R H. Drug-induced immune thrombocytopenia: an overview of pathogenesis. Semin Hematol. 1999; 36 2-6
- 29 Peter K, Schwarz M, Ylanne J et al.. Related articles, links free full text induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors. Blood. 1998; 92 3240-3249
- 30 Peter K, Straub A, Kohler B et al.. Platelet activation as a potential mechanism of GPIIb/IIIa inhibitor-induced thrombocytopenia. Am J Cardiol. 1999; 84 519-524
- 31 Ndoko S, Poujol C, Combrie R, Nurden A, Nurden P. Paradoxical platelet activation was not observed on dissociation of abciximab from GPIIb-IIIa complexes. Thromb Haemost. 2002; 87 317-322
- 32 Gawaz M, Neumann F J, Schomig A. Evaluation of platelet membrane glycoproteins in coronary artery disease: consequences for diagnosis and therapy. Circulation. 1999; 99 E1-E11
- 33 Rossi F, Rossi E, Pareti F I, Colli S, Tremoli E, Gallo L. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion. Haematologica. 2001; 86 192-198
- 34 Cazes E, Nurden P, Nurden A T. Abciximab binding to glycoprotein IIb-IIa and protein tyrosine phosphorylation in human platelets. Blood. 1999; 93 4019-4020
- 35 Osterland C K, Harboe M, Kunkel H G. Anti-gamma globulin factors in human sera revealed by enzymatic splitting of anti-Rh antibodies. Vox Sang. 1963; 8 133-152
- 36 Persselin J E, Stevens R H. Anti-Fab antibodies in humans: predominance of minor immunoglobulin G subclasses in rheumatoid arthritis. J Clin Invest. 1985; 76 723-730
- 37 Knight D M, Wagner C, Jordan R et al.. The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions. Mol Immunol. 1995; 32 1271-1281
- 38 Curtis B R, Divgi A, Garritty M, Aster R H. Delayed thrombocytopenia after treatment with abciximab: a distinct clinical entity associated with the immune response to the drug. J Thromb Haemost. 2004; 2 985-992
- 39 Warkentin T E. Laboratory testing for heparin-induced thrombocytopenia. J Thromb Thrombolysis. 2000; 10(suppl 1) 35-45
- 40 Bennett C L, Connors J M, Carwile J M et al.. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med. 2000; 342 1773-1777
- 41 Elmi F, Peacock T, Schiavone J. Isolated profound thrombocytopenia associated with clopidogrel. J Invasive Cardiol. 2000; 12 532-535
- 42 Christopolous C G, Machin S J. A new type of pseudo-thrombocytopenia: EDTA-mediated agglutination of platelets bearing Fab fragments of a chimeric antibody. Br J Hacmatol. 1994; 87 650-652
- 43 Sane D C, Damaraju L V, Topol E J et al.. Occurrence and clinical significance of pseudo-thrombocytopenia during abciximab therapy. J Am Coll Cardiol. 2000; 36 75-83
- 44 Phillips D R, Scarborough R M. Clinical pharmacology of eptifibatide. Am J Cardiol. 1997; 80 11B-20B
- 45 Kondo K, Umemura K. Clinical pharmacokinetics of tirofiban, a nonpeptide glycoprotein IIb/IIIa receptor antagonist: comparison with the monoclonal antibody abciximab. Clin Pharmacokinet. 2002; 41 187-195
- 46 Sieffert D, Stern A M, Ebling W et al.. Prospective testing for drug-dependent antibodies reduces the incidence of thrombocytopenia observed with the small molecule glycoprotein IIb/IIIa antagonist roxifiban: implications for the etiology of thrombocytopenia. Blood. 2003; 101 58-63
- 47 PURSUIT Trial Investigators . Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med. 1998; 339 436-443
- 48 PRISM-PLUS Trial Investigators . Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med. 1998; 338 1488-1497
- 49 McClure M W, Berkowitz S D, Sparapani R et al.. Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. Circulation. 1999; 99 2892-2900
- 50 RESTORE Trial Investigators . Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation. 1997; 96 1445-1453
- 51 Paradiso-Hardy F L, Madan M, Radhakrishnan S, Hurden S, Cohen E A. Severe thrombocytopenia possibly related to readministration of eptifibatide. Catheter Cardiovasc Interv. 2001; 54 63-67
- 52 Bougie D W, Wilker P R, Wuitschick E D et al.. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. Blood. 2002; 100 2071-2076
- 53 Salengro E, Mulvihill N T, Farah B. Acute profound thrombocytopenia after use of eptifibatide for coronary stenting. Catheter Cardiovasc Interv. 2003; 58 73-75
- 54 Tanaka K A, Vega J D, Kelly A B, Hanson S R, Levy J H. Eptifibatide-induced thrombocytopenia and coronary bypass operation. J Thromb Haemost. 2003; 1 392-394
- 55 Nagge J, Jackevicius C, Dzavik V, Ross J R, Seidelin P. Acute profound thrombocytopenia associated with eptifibatide therapy. Pharmacotherapy. 2003; 23 374-379
- 56 Morel O, Jesel L, Chauvin M, Freyssinet J M, Toti F. Eptifibatide-induced thrombocytopenia and circulating procoagulant platelet-derived microparticles in a patient with acute coronary syndrome. J Thromb Haemost. 2003; 1 2685-2687
- 57 Rezkalla S H, Hayes J J, Curtis B R, Aster R H. Eptifibatide-induced acute profound thrombocytopenia presenting as refractory hypotension. Catheter Cardiovas Interv. 2003; 58 76-79
- 58 Yoder M, Edwards R F. Reversible thrombocytopenia associated with eptifibatide. Ann Pharmacother. 2002; 36 628-30c
- 59 Suleiman M, Gruberg L, Hammerman H et al.. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, eptifibatide and abciximab: outcomes, complications and thrombocytopenia during percutaneous coronary intervention. J Invasive Cardiol. 2003; 15 319-323
- 60 Khaykin Y, Paradiso-Hardy F L, Madan M. Acute thrombocytopenia associated with eptifibatide therapy. Can J Cardiol. 2003; 19 797-801
- 61 Brassard J A, Curtis B R, Cooper R A et al.. Acute thrombocytopenia in patients treated with the oral glycoprotein IIb/IIIa inhibitors xemilofiban and orbofiban: evidence for an immune etiology. Thromb Haemost. 2002; 88 892-897
- 62 Billheimer J T, Dicker I B, Wynn R et al.. Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated. Blood. 2002; 99 3540-3546
- 63 Matzdorff A C, Kuhnel G, Kemkes-Matthes B, Pralle H, Voss R, Fareed J. Effect of glycoprotein IIb/IIIa inhibitors on CD62p expression, platelet aggregates, and microparticles in vitro. J Lab Clin Med. 2000; 135 247-255
- 64 Cox D, Smith R, Quinn M, Theroux P, Crean P, Fitzgerald D J. Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes. J Am Coll Cardiol. 2000; 36 1514-1519
- 65 Holmes M B, Sobel B E, Cannon C P, Schneider D J. Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: an OPUS-TIMI 16 substudy. Orbofiban in patients with unstable coronary syndromes. Thrombolysis in myocardial infarction. Am J Cardiol. 2000; 85 491-493
- 66 Frelinger A L, Furman M I, Krueger L A, Barnard M R, Michelson A D. Dissociation of glycoprotein IIb/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation. Circulation. 2001; 104 1374-1379
- 67 Seiffert D, Thomas B E, Bradley J D et al.. Effects of the glycoprotein IIb/IIIa antagonist Roxifiban on P-selectin expression, fibrinogen binding, and microaggregate formation in a phase I dose-finding study: no evidence for platelet activation during treatment with a glycoprotein IIb/IIIa antagonist. Platelets. 2003; 14 179-187
- 68 Bednar B, Cook J J, Holahan M A et al.. Fibrinogen receptor antagonist-induced thrombocytopenia in chimpanzee and rhesus monkey associated with preexisting drug-dependent antibodies to platelet glycoprotein IIb/IIIa. Blood. 1999; 94 587-599
- 69 Dunkley S, Lindeman R, Evans S, Casten R, Jepson N. Evidence of platelet activation due to tirofiban-dependent platelet antibodies: double trouble. J Thromb Haemost. 2003; 1 2248-2250
- 70 Kouns W C, Kirchhofer D, Hadváry P et al.. Reversible conformational changes induced in glycoprotein IIb-IIIa by a potent and selective peptidomimetic inhibitor. Blood. 1992; 80 2539-2547
- 71 Kunicki T J, Annis D S, Deng Y-J, Loftus J C, Shattil S J. A molecular basis for affinity modulation of Fab ligand binding to integrin alphaIIbbeta33 . J Biol Chem. 1996; 271 20315-20321
Richard H AsterM.D.
Blood Research Institute, Blood Center of Southeastern Wisconsin
P.O. Box 2178, Milwaukee, WI 53201-2178
Email: rhaster@bcsew.edu